ES2633145T3 - Anticuerpos dirigidos contra IL-17 - Google Patents
Anticuerpos dirigidos contra IL-17 Download PDFInfo
- Publication number
- ES2633145T3 ES2633145T3 ES11815158.8T ES11815158T ES2633145T3 ES 2633145 T3 ES2633145 T3 ES 2633145T3 ES 11815158 T ES11815158 T ES 11815158T ES 2633145 T3 ES2633145 T3 ES 2633145T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- antibody
- binding agent
- residue
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37097810P | 2010-08-05 | 2010-08-05 | |
| US370978P | 2010-08-05 | ||
| PCT/US2011/046201 WO2012018767A2 (en) | 2010-08-05 | 2011-08-02 | Antibodies directed against il-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2633145T3 true ES2633145T3 (es) | 2017-09-19 |
Family
ID=45560018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11815158.8T Active ES2633145T3 (es) | 2010-08-05 | 2011-08-02 | Anticuerpos dirigidos contra IL-17 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9328166B2 (https=) |
| EP (1) | EP2601217B1 (https=) |
| JP (1) | JP2013537414A (https=) |
| CN (1) | CN103154026B (https=) |
| AU (1) | AU2011285922B2 (https=) |
| BR (1) | BR112013002831A2 (https=) |
| ES (1) | ES2633145T3 (https=) |
| NZ (1) | NZ607615A (https=) |
| RU (1) | RU2595385C2 (https=) |
| WO (1) | WO2012018767A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2577228C2 (ru) * | 2014-03-14 | 2016-03-10 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CN108251431B (zh) | 2015-03-05 | 2020-12-08 | 北京百特美博生物科技有限公司 | 双载体系统及其用途 |
| CN109053884A (zh) * | 2015-11-02 | 2018-12-21 | 东南大学 | Wasabi蛋白纳米抗体及其编码序列与应用 |
| CN107236041B (zh) * | 2016-03-29 | 2020-07-24 | 舒泰神（北京）生物制药股份有限公司 | Il-17抗体 |
| CN107488227A (zh) * | 2016-06-12 | 2017-12-19 | 三生国健药业（上海）股份有限公司 | 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用 |
| US11619832B2 (en) | 2018-03-08 | 2023-04-04 | Coopervision International Limited | Identification of contact lens wearers predisposed to contact lens discomfort |
| JP7525499B2 (ja) | 2019-01-31 | 2024-07-30 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法 |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| EP3965818A4 (en) | 2019-05-08 | 2023-05-31 | Janssen Biotech, Inc. | MATERIALS AND METHODS FOR MODULATION OF T-CELL-MEDIATED IMMUNITY |
| AR123935A1 (es) * | 2020-10-28 | 2023-01-25 | Janssen Biotech Inc | COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g |
| CN112646030B (zh) * | 2021-01-11 | 2021-11-30 | 内蒙古创润生物科技有限公司 | 一种包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用 |
| CN121731462A (zh) * | 2024-09-27 | 2026-03-27 | 百奥泰生物制药股份有限公司 | 抗il-17抗体制剂及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2508214A1 (en) * | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to phospholipase a2 and uses thereof |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| CN101326195B9 (zh) | 2005-12-13 | 2022-11-11 | 伊莱利利公司 | 抗il-17抗体 |
| JP5068270B2 (ja) | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのｉｌ−１７アンタゴニスト抗体 |
| GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| CA2660463C (en) * | 2006-08-11 | 2013-07-16 | Schering Corporation | Antibodies to il-17a |
| JP5581323B2 (ja) | 2008-09-29 | 2014-08-27 | ロシュ グリクアート アクチェンゲゼルシャフト | ヒトｉｌ１７に対する抗体およびその使用 |
| WO2011056864A1 (en) | 2009-11-05 | 2011-05-12 | Anaptysbio, Inc. | Methods of generating improved antigen-binding agents using chain shuffling and optionally somatic hypermutation |
-
2011
- 2011-08-02 BR BR112013002831A patent/BR112013002831A2/pt not_active Application Discontinuation
- 2011-08-02 CN CN201180048098.2A patent/CN103154026B/zh active Active
- 2011-08-02 RU RU2013109397/10A patent/RU2595385C2/ru active
- 2011-08-02 NZ NZ60761511A patent/NZ607615A/en unknown
- 2011-08-02 ES ES11815158.8T patent/ES2633145T3/es active Active
- 2011-08-02 WO PCT/US2011/046201 patent/WO2012018767A2/en not_active Ceased
- 2011-08-02 EP EP11815158.8A patent/EP2601217B1/en active Active
- 2011-08-02 AU AU2011285922A patent/AU2011285922B2/en active Active
- 2011-08-02 JP JP2013523260A patent/JP2013537414A/ja active Pending
- 2011-08-02 US US13/814,262 patent/US9328166B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013537414A (ja) | 2013-10-03 |
| WO2012018767A2 (en) | 2012-02-09 |
| AU2011285922B2 (en) | 2016-06-16 |
| EP2601217B1 (en) | 2017-06-14 |
| US9328166B2 (en) | 2016-05-03 |
| CN103154026B (zh) | 2016-07-06 |
| RU2013109397A (ru) | 2014-09-10 |
| RU2595385C2 (ru) | 2016-08-27 |
| CN103154026A (zh) | 2013-06-12 |
| EP2601217A4 (en) | 2014-03-05 |
| AU2011285922A1 (en) | 2013-03-21 |
| NZ607615A (en) | 2015-03-27 |
| US20130202591A1 (en) | 2013-08-08 |
| BR112013002831A2 (pt) | 2016-11-01 |
| WO2012018767A3 (en) | 2012-05-10 |
| EP2601217A2 (en) | 2013-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2633145T3 (es) | Anticuerpos dirigidos contra IL-17 | |
| US11999783B2 (en) | Method of treating autoimmune disease with antibodies against IL-33 | |
| ES2959463T3 (es) | Método seguro y eficaz para tratar la colitis ulcerativa con anticuerpo anti-il12/il23 | |
| ES2710289T3 (es) | Anticuerpos anti-IL-23, composiciones, procedimientos y usos | |
| ES2335232T3 (es) | Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta. | |
| ES2347690T3 (es) | Anticuerpos anti-il-23. | |
| ES2615978T3 (es) | Moléculas de anticuerpo que tienen especificidad de unión por IL-13 humana | |
| ES2828482T3 (es) | Anticuerpos contra el g-csfr y su uso | |
| CN103261223B (zh) | 人制瘤素m抗体及使用方法 | |
| ES2525325T3 (es) | Moléculas de anticuerpo que tienen especificidad por la IL-6 humana | |
| KR20110043761A (ko) | 항-ｉｌ-12/ｉｌ-23 항체 | |
| ES2728438T3 (es) | Anticuerpo anti-receptor de IL-23 humano nuevo | |
| ES3039616T3 (en) | Anti-il-6 vaccine composition | |
| ES2665851T3 (es) | Nuevo anticuerpo anti-CTGF humano | |
| KR20230084283A (ko) | 항-il12/il23 항체로 크론병을 치료하는 방법 | |
| KR20220141847A (ko) | 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법 | |
| CN120569403A (zh) | 用抗il23特异性抗体治疗溃疡性结肠炎的方法 | |
| US20260062472A1 (en) | Bispecific antibody and use thereof | |
| CN118401550A (zh) | 用抗il23特异性抗体治疗溃疡性结肠炎的方法 | |
| RU2829846C2 (ru) | Антитела, направленные против интерлейкина-33 (il-33) | |
| HK1231082A1 (en) | Antibodies directed against interleukin-33 (il-33) | |
| HK1231082B (en) | Antibodies directed against interleukin-33 (il-33) |